Skip to contentpdufa.bio

onvansertib Investigator-sponsored

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

onvansertib Investigator-sponsored is a Cardiff Oncology, Inc. program in chronic myelomonocytic leukemia (CMML). Its next catalyst is a Readout on Dec 13, 2026.

CRDF catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: chronic myelomonocytic leukemia (CMML). Sponsor: Cardiff Oncology, Inc. (CRDF). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Dec 13, 2026CRDF

Questions

When is onvansertib Investigator-sponsored's next FDA decision or readout?

The next tracked catalyst for onvansertib Investigator-sponsored is a Readout on Dec 13, 2026.

What happened at onvansertib Investigator-sponsored's most recent FDA decision?

No FDA decision for onvansertib Investigator-sponsored is in our archive yet.

What is onvansertib Investigator-sponsored used for?

In our records onvansertib Investigator-sponsored is under review or in development for chronic myelomonocytic leukemia (CMML).

Who makes onvansertib Investigator-sponsored?

Cardiff Oncology, Inc. (CRDF).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.